Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Starting or Strengthening a Drug Bulletin - A Practical Manual
(2005; 165 pages) View the PDF document
Table of Contents
View the documentPreface
View the documentHow the manual was produced
View the documentAbout ISDB
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Rational use of medicines
Open this folder and view contents3. What are drug bulletins?
Open this folder and view contents4. Defining aims, target and type of bulletin
Open this folder and view contents5. Planning resources
Open this folder and view contents6. Planning bulletin production: schedules and timing
Open this folder and view contents7. The editorial process
Open this folder and view contents8. Reviewing a new drug: is it a therapeutic advance?
Open this folder and view contentsAnnexe to Chapter 8: Evaluating harm
Open this folder and view contents9. Design and production
Open this folder and view contents10. Dissemination
Open this folder and view contents11. Organizational and legal issues
Open this folder and view contents12. Evaluating quality and usefulness
Open this folder and view contents13. Partnership and collaboration
Open this folder and view contents14. Keeping records and creating a memory
Open this folder and view contentsAppendix: Electronic sources of information
 

How the manual was produced

In 1998, ISDB, in collaboration with WHO, embarked on a joint project to develop and publish a manual aimed at helping people start or strengthen a drug bulletin. ISDB and WHO share a commitment to promoting rational drug use and see drug bulletins as important tools in this respect. WHO has worked together with ISDB in a number of areas and has supported ISDB training schools and regional meetings, in particular enabling people working on drug bulletins in developing countries to participate. Ideas for the manual grew out of this collaboration.

The aim of the manual project was to harness the insights of those with day-to-day experience of producing independent drug bulletins. It was agreed that the best way of reflecting the diversity of drug bulletins was to involve many people working in different countries for a variety of bulletins. The process of drafting and reviewing the manual has therefore depended on the active participation of many people, mainly editors from ISDB member bulletins.

Much of the writing and reviewing had been done by September 1999, when unfortunately, work on the manual stopped. At the 2002 general assembly of ISDB in Dubrovnik, regrets were expressed that the manual had not been published and it was agreed that efforts should be made to complete the project. A manual editorial team was formed in 2003 to do that. Working in collaboration with the Department of Medicines Policy and Standards at WHO, the editorial team has brought the text up-to-date and added new sections.

People who have worked on the manual

The following people drafted chapters:

Ilze Aizsilniece, Wilbert Bannenberg, Danielle Bardelay, Hiro Beppu, Joe Collier, Marg Ewen, Henkjan Gebben, Rokuro Hama, Andrew Herxheimer, Catherine Hodgkin, Ellen ‘t Hoen, Malena Jirlow, Mohan Joshi, Zafar Mirza, Abdul Dzulkifli Razak, Jose Maria Recalde, Georgette Sanou, Jerome Sclafer, Andrea Tarr, Wil Toenders, Gianni Tognoni.

Chapter reviewers in 1998/9:

K. Balasubramaniam, Wilbert Bannenberg, Gilles Bardelay, Marc Bogaert, Montserrat Bosch, Dominique Broclain, Natalia Chebotarenko, Pierre Chirac, Joe Collier, Albano del Favero, John Dowden, Graham Dukes, Gita Fernando, Etzel Gysling, P. Hardjasaputra, Andrew Herxheimer, Marie Husson, Kees de Joncheere, Mohan Joshi, David Lee, Peter Mansfield, Geoffrey Obiaga, Blanka Pospisilova, Kirstin Raudsepp, Jose Recalde, Emilio Sanz, Pijus Sarkar, Kris Soenen, Sri Suryawati, Andrea Tarr, Molly Thomas, Wil Toenders, Gianni Tognoni, Bozidar Vrhovac, Hans Winkler, Sidney Wolfe.

Chapter reviewers from 2003:

Editors from ISDB member bulletins: Embaye Andom (Eritrea), Wolfgang Becker Brueser (Germany), Montserrat Bosch (Spain), Joe Collier (UK) John Dowden (Australia), Michel le Duff (France), Gita Fernando (Sri Lanka), Maria Font (Italy), Amitava Guha (India), Sharon Hart (UK), Ciprian Jauca (Canada), K.K. Kafle (Nepal), Saliya Karymbaeva (Kyrgyzstan), Joan-Ramon Laporte (Spain), Peter Lurie (USA), Benoit Marchand (Nicaragua), Zahed Masud (Bangladesh), Paul McManus (UK), Promila Pandhi (India), Blanka Pospisilova (Czech Republic), Neus Rams (Spain), Emilio Sanz (Spain), Jan Schuling (Netherlands), Bhupendra Thapa (Nepal), Walter Thimme (Germany), Gianni Tognoni (Italy), Zaeem ul Haq (Pakistan), Sarita von Afehlt (New Zealand), Bozidar Vrhovac (Croatia).

Also:

Warren Kaplan, Center for International Health and Development, Boston University School of Public Health, USA; Kate Hawkins, Market Research, Which Ltd. UK; Neil Pakenham- Walsh, International Network for Access to Scientific Publications (INASP); Richard Laing, Kath Hurst, Department of Medicines Policy and Standards, WHO.

Manual coordinator in 1998/9

The first phase of work on the manual was coordinated by Daphne Fresle (working for WHO in the unit formerly known as the Action Programme on Essential Drugs). Ellen ‘t Hoen and Catherine Hodgkin also worked on the manual during this phase.

Manual editorial team (from 2003)

Danielle Bardelay (France), Andrew Herxheimer (UK), Rokuro Hama (Japan), Benoit Marchand (Nicaragua), Andrea Tarr (coordinator) (UK).

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014